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ABSTRACT	39	
Aim:	Gut	microbial	dysbiosis	is	implicated	in	the	pathogenesis	of	non-alcoholic	40	
steatohepatitis	(NASH).	We	investigated	downstream	effects	of	gut	microbiota	modulation	41	
on	markers	of	hepatic	inflammation,	steatosis,	and	hepatic	and	peripheral	insulin	sensitivity	42	
in	patients	with	NASH	using	Rifaximin	therapy.	43	
Methods:	Patients	with	biopsy-proven	NASH	and	elevated	aminotransferase	values	were	44	
included	in	this	open-label	pilot	study,	all	receiving	6	weeks	Rifaximin	400mg	twice	daily,	45	
followed	by	a	6	week	observation	period.	The	primary	endpoint	was	change	in	ALT	after	6	46	
weeks	of	Rifaximin.	Secondary	endpoints	were	change	in	hepatic	lipid	content	and	insulin	47	
sensitivity	measured	with	a	hyperinsulinaemic	euglycaemic	clamp.	48	
Results:	Fifteen	patients,	13	male,	2	female,	with	median	(range)	age	46(32-63)	years	were	49	
included.	Seven	had	diabetes	on	oral	hypoglycaemic	medications	and	8	had	no	diabetes.	50	
After	6	weeks	of	therapy,	no	differences	were	seen	in	ALT	(55	[33-191]	versus	63	[41-51	
218]IU/L,	p=0.41),	peripheral	glucose	uptake	(28.9	[19.4-48.3]	to	25.5	[17.7-47.9]	52	
µmol/kg/min,	p=0.30),	hepatic	insulin	sensitivity	(35.2	[15.3-51.7]%	versus	30.0	[10.8-53	
50.5]%,	p=0.47),	or	hepatic	lipid	content	(21.6[2.2-46.2]%	before	and	24.8[1.7-59.3]%	after	54	
Rifaximin,	p=0.59)	before	and	after	Rifaximin	treatment.		After	12	weeks	from	baseline,	55	
serum	ALT	increased	to	83(30-217)IU/L,	p=0.02.	There	was	a	significant	increase	in	HOMA-IR	56	
(p=0.05).	The	urinary	metabolic	profile	indicated	a	significant	reduction	in	urinary	hippurate	57	
with	treatment,	which	reverted	to	baseline	after	cessation	of	Rifaximin,	although	there	was	58	
no	consistent	difference	in	relative	abundance	of	faecal	microbiota	with	treatment.		59	
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Conclusion:	These	data	do	not	indicate	a	beneficial	effect	of	Rifaximin	in	patients	with	60	
NASH.		61	
Abstract	248	words	(max	250)	62	
	63	
Key	words:	64	
Antibiotic;	Hippurate;	Insulin	resistance;	Microbiota;	NAFLD;	Non-alcoholic	steatohepatitis	65	
	66	
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INTRODUCTION	68	
Non-alcoholic	fatty	liver	disease	(NAFLD)	is	the	most	common	cause	of	liver	dysfunction	and	69	
an	increasing	cause	of	liver-related	morbidity	and	mortality	globally(1,	2).	NAFLD,	and	its	70	
inflammatory	and	potentially	progressive	subtype,	non-alcoholic	steatohepatitis	(NASH),	71	
represents	a	complex	disease	trait,	with	genetic	and	environmental	influences	on	incidence	72	
and	disease	progression(2,	3).	While	lifestyle	measures	in	order	to	achieve	sustained	weight	73	
loss,	including	dietary	changes	and	regular	exercise	are	the	mainstay	of	current	74	
management(4),	many	patients	do	not	respond	to	such	measures	and	specific	therapies	are	75	
lacking(5,	6).	76	
	77	
The	gut	microbiota	is	increasingly	recognised	as	a	key	metabolic	influence	in	the	body	and	a	78	
potentially	modifiable	environmental	target	in	disorders	of	energy	metabolism	and	fat	79	
storage(7).		Mechanisms	include	increase	of	calorific	yield	of	meals	by	co-digestion,	80	
production	of	short	chain	fatty	acids	and	bacterial	endotoxin	(7,	8)(9).		81	
	82	
Microbial	interventions,	such	as	transfer	of	caecal	contents	from	conventionally-raised	mice	83	
to	germ	free	mice	have	been	shown	to	alter	the	host	phenotype(7),	while	a	study	in	patients	84	
with	the	metabolic	syndrome	demonstrated	improved	insulin	sensitivity	in	patients	85	
receiving	a	faecal	allogenic	enteric	infusion	from	a	lean	donor	than	from	an	autologous	86	
infusion(10).	Besides	direct	microbial	transfer,	other	methods	for	alteration	of	the	gut	87	
microbiota	include	use	of	prebiotics,	probiotics	and	antibiotics(11).	Antibiotic	therapy	in	88	
obese	mice	reduced	LPS	and	improved	the	metabolic	phenotype(12),	while	Rifaximin	was	89	
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found	to	reduce	endotoxinaemia	in	patients	with	decompensated	cirrhosis,	associated	with	90	
improvements	in	hepatic	synthetic	function,	but	not	aminotransferase	values(13).	91	
	92	
Rifaximin	is	a	minimally-absorbed,	broad	spectrum	antibiotic,	which	has	been	found	to	have	93	
clinical	utility	in	a	number	of	gastrointestinal	settings	with	few	side	effects(14-16).	With	94	
standard	oral	dosing,	intraluminal	drug	levels	exceed	the	minimum	inhibitory	95	
concentrations	for	most	bacterial	species	by	up	to	250-fold,	while	systemic	absorption	is	96	
<0.4%	of	the	dose(17).		97	
	98	
We	hypothesised	that	modulation	of	the	gut	microbiota,	using	Rifaximin,	in	humans	with	99	
NASH	would	lead	to	improvement	in	hepatic	inflammation,	hepatic	lipid	content	and	insulin	100	
sensitivity.	Thus,	we	conducted	a	pilot	prospective	clinical	trial	to	evaluate	the	efficacy	and	101	
safety	of	such	an	approach.	We	examined	the	faecal	microbiota,	urinary	metabolome	and	102	
inflammatory	cytokine	profile	as	secondary	analyses	to	assess	whether	any	changes	103	
observed	were	linked	to	detectable	differences	in	bacterial	populations,	to	microbial	co-104	
metabolism	and	whether	this	could	be	mediated	by	inflammatory	signalling.	105	
	106	
METHODS	107	
Ethical	approval	(REC	10/H0711/58)	was	obtained	and	the	study	was	registered	on	the	108	
European	Clinical	Trials	Database	(EudraCT	2010-021515-17).	Patients	were	recruited	from	109	
Hepatology	clinics	at	a	single	UK	centre	(Imperial	College	Healthcare	NHS	Trust)	between	110	
May	2011	and	June	2012.	Informed	consent	was	obtained	from	all	patients	included	in	the	111	
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study	and	the	study	protocol	conforms	to	the	ethical	guidelines	of	the	1975	Declaration	of	112	
Helsinki	as	reflected	in	a	priori	approval	by	the	institution's	human	research	and	ethics	113	
committee	(West	London	REC	2).	Male	and	female	patients	were	eligible	for	inclusion	if	114	
aged	between	18	and	70	years	with	non-alcoholic	steatohepatitis	histologically-proven,	as	115	
evidenced	by	the	presence	of	all	of:	steatosis,	hepatocyte	ballooning	and	lobular	116	
inflammation,	and	scored	according	to	Kleiner(18)	by	a	single	experienced	histopathologist	117	
(RDG)	within	the	previous	year,	with	or	without	mild	to	moderate	fibrosis	(stage	0-3/4)	and	118	
with	persistently	elevated	alanine	aminotransferase	(ALT)	values	on	at	least	two	occasions	119	
in	the	three	months	prior	to	recruitment.	Patients	were	excluded	if	there	was	histological	120	
evidence	of	cirrhosis;	hepatic	decompensation;	regular	alcohol	consumption	exceeding	14	121	
units/week	(16g	ethanol/day)	for	a	woman	or	21	units/week	(24g	ethanol/day)	for	a	man;	122	
evidence	of	viral,	autoimmune	or	other	metabolic	liver	disease	on	a	chronic	liver	disease	123	
screen;	a	history	of	malignancy	or	systemic	inflammatory	conditions;	myocardial	infarction	124	
or	cerebrovascular	events	in	the	preceding	6	months;	a	history	of	bariatric	surgery,	blind	125	
loop	or	short	bowel;	use	of	any	treatment	known	or	suspected	to	change	bowel	flora	within	126	
3	months	of	enrolment;	initiation	or	major	dose	change	of	metformin,	thiazolinediones,	127	
biguanides,	statins,	fibrates,	anti-obesity	medications	or	insulin	within	3	months	of	128	
enrolment.	129	
	130	
Study	design	131	
This	was	an	open-label	study	of	Rifaximin	(Normix,	Alfa	Wasserman	S.p.A,	Bologna,	Italy)	132	
400mg	twice	daily	for	six	weeks	followed	by	a	further	six	weeks	observation	period	during	133	
which	patients	received	standard	care.	Compliance	with	treatment	was	checked	by	134	
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collection	of	empty	blister	packs.	Subjects	were	asked	to	provide	a	structured	dietary	and	135	
lifestyle	history	as	previously	described(19).	The	primary	endpoint	was	change	in	ALT	after	6	136	
weeks’	Rifaximin	therapy.	Secondary	endpoints	were	change	in	hepatic	and	whole-body	137	
insulin	sensitivity	assessed	by	the	two-stage	hyperinsulinaemic	euglycaemic	clamp	and	138	
change	in	hepatic	triglyceride	content	assessed	by	proton	nuclear	magnetic	resonance	139	
spectroscopy	at	6	weeks	from	baseline.	Serum	ALT,	biochemistry	and	anthropometrics	were	140	
also	measured	at	12	weeks	to	look	for	longer-term	effects.	Stool	microbiota,	urinary	141	
metabolic	profile	and	serum	cytokine	profile	were	measured	before	and	after	intervention.		142	
Laboratory	measurement	143	
Routine	biochemistry	was	undertaken	by	the	hospital	biochemistry	laboratory	on	the	144	
Aeroset	(ALT,	AST,	HDL,	triglyceride)	or	Architect	(insulin)	clinical	chemistry	analyser	145	
platforms	(Abbott	Diagnostics,	Illinois,	USA).	Insulin	concentrations	were	determined	using	a	146	
one-step	chemiluminescent	immunoassay.	Cytokine	analysis	was	performed	by	Aushon	147	
Multiplex	Immunoassay	Analysis	(Aushon	Biosystems,	Billerica,	USA).	148	
Hyperinsulinaemic	euglycaemic	clamp	149	
The	two-step	hyperinsulinaemic	euglycaemic	clamp	combined	with	a	[6,6-2H2]glucose	150	
infusion	to	measure	insulin	sensitivity	was	performed	as	previously	described	and	detailed	151	
in	the	supplementary	information	(20).	Patients	consumed	nothing	but	water	orally	after	152	
eating	a	low-fat	pre-prepared	meal	(identical	before	and	after	intervention)	10	hours	prior	153	
to	the	clamp	study.		154	
Plasma	glucose	concentration	and	enrichment	time-courses	were	smoothed	using	optimal	155	
segments	analysis(21)	and	non-steady-state	equations(22)	156	
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	157	
Proton	nuclear	magnetic	resonance	spectroscopy	158	
Patients	fasted	for	at	least	10	hours	prior	to	scanning.		Rapid	T1-weighted	magnetic	159	
resonance	images	were	acquired	using	a	1.5T	Phillips	AchievaTM	scanner	(Philips	Medical	160	
Systems,	Best,	Netherlands),	as	previously	described(23).	Proton	nuclear	magnetic	161	
resonance	(1H	NMR)	spectra	were	acquired	at	1.5T,	using	a	surface	coil.	Transverse	images	162	
of	the	liver	were	used	to	ensure	accurate	positioning	of	the	(20x20x20	mm)	voxel	in	the	163	
liver,	avoiding	blood	vessels,	the	gall	bladder	and	fatty	tissue.	Spectra	were	obtained	from	164	
the	right	lobe	of	the	liver	using	a	PRESS	sequence	(TR	1500ms,	TE	135	ms)	without	water	165	
saturation	and	with	128	signal	averages.	Intrahepatocellular	lipids	(IHCL)	were	measured	166	
relative	to	liver	water	content,	as	previously	described(24).		167	
Faecal	microbiota	168	
Faeces	were	collected	in	a	sterile	container	at	each	assessment	visit	and	frozen	at	-70⁰C	169	
within	10	minutes.	DNA	was	extracted	using	a	Qiagen	DNA	stool	extraction	kit	(Qiagen,	170	
Manchester,	UK),	with	an	additional	bead	beating	step	added	before	the	ASL	buffer	was	171	
added	to	the	stool	sample.	The	extracted	DNA	was	quantified	using	a	Qubit	platform	and	all	172	
DNA	samples	were	normalised	to	10	ng/µL.	The	16S	rRNA	gene	was	amplified	using	primers	173	
for	the	V1	to	V3	regions	and	sequenced	using	paired	end	250bp	chemistry	on	an	Illumina	174	
MiSeq	platform	(Illumina	Inc,	San	Diego,	California).	The	data	were	analysed	using	175	
bioinformatics	statistical	packages	(Mothur,	STAMP)	and	R	(R	Foundation,	Vienna,	Austria)	176	
to	determine	whether	any	statistically	significant	changes	in	the	profiles	of	the	faecal	177	
microbiota	had	occurred(25-27).	178	
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	179	
Urinary	metabolomics	180	
Urine	was	collected,	processed	and	buffered	as	detailed	in	the	supplementary	information.	181	
All	NMR	spectra	were	referenced,	phased	and	baselined	corrected	as	detailed	in	the	182	
supplementary	information.	Data	were	initially	modelled	using	unsupervised	principle	183	
components	analysis	(PCA)	and	subsequently	combined	with	clinical	data	and	modelled	184	
using	orthogonal	partial	least	squares	discriminant	analysis	(OPLS-DA).	For	univariate	185	
analyses	Topspin	(Bruker,	Billerica,	USA)	was	used	to	integrate	under	spectral	resonances	186	
for	metabolites	of	interest	and	the	quantitative	data	was	analysed	in	the	statistics	package	187	
SPSS	(IBM,	Armonk,	USA).	188	
Statistical	analysis	189	
Statistical	analyses	were	performed	using	SPSS	20.0	(SPSS	Inc.,	Chicago,	USA).	Based	on	190	
historical	data	from	20	patients	with	paired	ALT	data	in	response	to	lifestyle	and	standard	of	191	
care	intervention	from	the	NAFLD	clinic	at	our	institution,	a	sample	size	of	16	would	provide	192	
80%	power	and	a	of	0.05	to	detect	a	change	in	ALT	of	25IU/L	with	an	expected	standard	193	
deviation	of	the	difference	of	33IU/L.	Data	were	non-parametrically	distributed,	so	are	194	
displayed	as	median	(range).	Significance	of	differences	in	endpoints	before	and	after	195	
intervention	was	tested	by	the	Wilcoxon	Signed	Rank	test.		196	
	197	
RESULTS	198	
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Of	the	77	patients	with	biopsy-proven	NAFLD	evaluated	in	clinic	over	the	recruitment	199	
period,	41	met	inclusion	criteria	and	were	invited	to	take	part	in	the	study.	On	receipt	of	the	200	
patient	information,	18	patients	declined	to	participate	and	23	were	screened.	Of	these,	a	201	
further	two	declined	to	participate	further	at	the	screening	visit	and	three	were	excluded	by	202	
the	screening	questionnaire.	Of	the	15	patients	who	initiated	the	study	protocol,	one	203	
participant	was	unable	to	tolerate	MR	scanning	owing	to	claustrophobia	and	another	204	
participant	declined	the	hyperinsulinaemic	euglycaemic	clamp	having	already	started	the	205	
study.		Baseline	patient	characteristics	are	displayed	in	Table	1.	100%	compliance	with	206	
Rifaximin	therapy	was	reported	by	all	participants.	One	subject	noted	loose	stools	for	36	207	
hours	during	therapy,	which	resolved	spontaneously	and	therapy	was	not	discontinued.	No	208	
other	adverse	events	were	recorded.	Recruitment	was	halted	after	enrolment	of	15	subjects	209	
because	of	difficulty	in	recruitment	to	the	full	study	protocol	over	the	defined	study	time	210	
period.	211	
Hepatocellular	inflammation	212	
Alanine	aminotransferase	(ALT)	values,	the	primary	endpoint	in	this	study,	were	55IU/L	(33-213	
191)	before	Rifaximin,	63IU/L	(41-218)	after	6	weeks’	Rifaximin	(p=0.41	compared	to	214	
baseline)	and	83IU/L	(30-217)	after	a	further	6	weeks	follow-up	(p=0.017	compared	to	215	
baseline),	Figure	1A.	Anthropometrics,	HOMA-IR	and	lipid	profile	before	and	after	Rifaximin	216	
are	shown	in	Table	2.	There	was	a	significant	increase	in	HDL	and	HOMA-IR	at	12	weeks.	217	
Hepatic	Lipid	content	218	
Hepatic	lipid	content	(IHCL)	was	21.6%	(2.2-46.2)	before	and	24.8%	(1.7-59.3)	after	219	
Rifaximin,	p=0.59.	Figure	1B.		220	
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Insulin	sensitivity	221	
Hepatic	insulin	sensitivity	as	assessed	by	suppression	of	hepatic	glucose	production	was	222	
35.2%	(15.3-51.7)	before	Rifaximin	and	30.0%	(10.8-50.5)	after	Rifaximin,	p=0.47,	Figure	1C.	223	
Peripheral	insulin	sensitivity	as	assessed	by	glucose	Rd	was	28.9	µmol/kg/min	(19.4-48.3)	224	
before	Rifaximin	and	25.5	µmol/kg/min	(17.7-47.9)	after	Rifaximin,	p=0.30,	Figure	1D.		225	
Cytokine	analysis	226	
There	were	no	differences	in	serum	cytokine	values,	including	TNFa	and	IL-1b,	before	and	227	
after	treatment	with	Rifaximin,	and	over	the	observation	periods	(Supplementary	Table	1).	228	
	229	
Urinary	metabonomics	230	
Urinary	metabolites	were	identified	as	seen	in	the	representative	urinary	metabolic	profile,	231	
Figure	2A.	Principal	components	analysis	of	urinary	metabolic	profiles	demonstrated	close	232	
clustering	of	quality	control	samples	and	case	samples	clustered	by	patient,	Figure	2B.	233	
Supervised	partial	least	squares	discriminant	analysis	(OPLS-DA)	failed	to	produce	robust,	234	
predictive	models	based	upon	the	effect	of	treatment	upon	urinary	metabolic	profiles.	235	
Examination	of	the	loadings	plots	for	the	OPLS-DA	models	identified	three	metabolites,	236	
alanine,	creatinine	and	hippurate,	with	modest	correlation	with	treatment	status,	Figure	2C.	237	
These	metabolites	were	examined	further	in	univariate	analyses,	Figure	2D.	A	significant	238	
decrease	in	hippurate	levels	was	observed	following	treatment	with	rifaximin	(p=0.048).	A	239	
significant	increase	in	hippurate	levels	was	seen	from	immediately	after	treatment	to	6	240	
weeks	after	its	discontinuation	(p=0.035);	no	difference	was	seen	between	6	weeks	post-241	
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treatment	and	pre-treatment	hippurate	levels	(p=0.721).	There	were	no	statistically	242	
significant	changes	in	alanine	or	creatinine	levels	with	treatment.	243	
	244	
Stool	Microbiota	245	
No	consistent	differences	were	observed	in	the	relative	abundance	of	gut	microbiota	at	the	246	
phylum	level	in	faeces	with	Rifaximin	treatment	(Figure	3).	However	significant	differences	247	
in	the	microbiota	were	seen	at	the	genus	level	in	individual	patients	with	Rifaximin	248	
treatment	(Supplementary	Figure	1,	published	online),	although	these	differences	were	not	249	
common	to	all	subjects.	250	
	251	
DISCUSSION	252	
In	this	study,	we	performed	an	open-label	clinical	trial	of	Rifaximin	in	patients	with	NASH	to	253	
test	effect	and	safety.	Although	there	was	no	evidence	of	change	in	markers	of	hepatic	254	
inflammation,	hepatic	lipid	content	or	insulin	sensitivity	after	6	weeks	of	therapy,	serum	ALT	255	
values	increased	significantly	from	baseline	to	12	weeks,	in	association	with	increased	256	
insulin	resistance	as	assessed	by	the	HOMA-IR	score.	An	increase	in	serum	HDL	values	was	257	
also	observed.	Univariate	analysis	of	urinary	hippurate	levels	suggests	that	treatment	258	
transiently	suppressed	the	production	of	this	metabolite.	However,	robust	changes	were	259	
not	demonstrated	in	the	faecal	microbiota,	or	a	panel	of	pro-	and	anti-inflammatory	serum	260	
cytokines.	No	adverse	events	were	recorded.	These	results	contrast	with	another	recent	261	
open	label	study	of	Rifaximin	in	NAFLD/NASH	which	reported	an	improvement	in	liver	262	
biochemistry,	body	mass	index	and	IL-10	after	28	days	of	Rifaximin	1200mg	per	day	in	27	263	
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patients	with	NASH,	although	insulin	sensitivity,	liver	fat	and	gut	microbiota	were	not	264	
assessed	specifically	in	that	study(28).	265	
	266	
Ours	was	a	prospective	clinical	study	in	which	subjects	were	intensively	investigated	to	look	267	
for	signals	of	biological	effect	of	Rifaximin	on	NASH	in	human	subjects	that	might	form	the	268	
basis	of	larger	studies	of	longer	duration.	The	sample	size	is	relatively	small,	but	the	study	269	
was	powered	to	detect	a	difference	in	ALT	of	25IU/L	with	treatment,	which	was	not	seen.	270	
This	study	included	more	patients	than	studies	using	the	hyperinsulinaemic	euglycaemic	271	
clamp	to	assess	the	effects	of	antibiotic	administration	and	faecal	transfer	on	insulin	272	
sensitivity(10,	29),	so	might	be	expected	to	show	a	difference	in	insulin	sensitivity	if	273	
Rifaximin	were	to	cause	an	effect	of	similar	magnitude	to	those	interventions.	The	study	was	274	
of	similar	size	to	studies	assessing	the	microbial	and	metabolic	effects	of	Rifaximin	in	275	
cirrhosis(30,	31)	and	the	effect	of	Rifaximin	on	liver	biochemistry	in	patients	with	PSC(32).	276	
Nevertheless,	the	study	was	not	powered	to	detect	differences	in	subgroups,	such	as	those	277	
with	and	without	type	2	diabetes	mellitus.	The	six-week	course	of	therapy	may	be	278	
considered	short,	but	metabolic	effects	of	antibiotics	are	seen	at	1	week(29)	and	changes	in	279	
hepatocellular	inflammation	are	detectable	rapidly	in	serum.	The	dose	of	Rifaximin	used	in	280	
this	study	is	lower	than	in	other	recent	clinical	trials	which	have	used	550mg	twice	daily,	a	281	
dose	licenced	for	use	in	the	secondary	prophylaxis	of	hepatic	encephalopathy(14).	This	282	
difference	reflects	the	Rifaximin	preparations	and	dosing	information	available,	and	the	283	
clinical	usage	for	gastrointestinal	infections	at	the	time	of	study	initiation.	Assessment	of	284	
changes	to	the	intestinal	microbiota	using	sequencing	of	faecal	bacterial	DNA	is	limited	as	285	
the	faecal	microbiota	may	not	reflect	the	metabolically	active	microbiota	at	the	small	bowel	286	
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mucosa,	which	are	implicated	in	the	effects	of	Rifaximin	and	more	readily	sampled	in	animal	287	
studies(33).		288	
	289	
Although	the	primary	and	secondary	outcome	measures	were	not	altered	by	Rifaximin	in	290	
this	study,	some	additional	markers	changed	post-treatment.	These	differences	were	not	291	
specified	in	the	a	priori	analysis	so	should	be	interpreted	tentatively	at	this	stage.	However,	292	
this,	and	other	studies,	suggest	that	some	broad	spectrum	oral	antibiotics,	including	293	
Rifaximin,	may	be	associated	with	adverse	metabolic	and	hepatic	responses.	For	example,	294	
oral	administration	of	a	short	course	of	vancomycin	reduced	peripheral	insulin	sensitivity	in	295	
patients	with	the	metabolic	syndrome,	in	association	with	reduced	gut	microbial	296	
diversity(29).	In	another	study	of		patients	with	cirrhosis	before	and	after	Rifaximin	297	
administration,	there	was	a	reduction	in	the	ratio	of	secondary	to	primary	bile	acids(31),	298	
suggesting	a	possible	mechanism	for	any	Rifaximin-induced	insulin	resistance.	As	in	the	299	
present	study,	previous	work	using	a	systems	biology	approach	to	evaluate	metabolic	and	300	
microbial	effects	of	Rifaximin	in	patients	with	cirrhosis	and	minimal	hepatic	encephalopathy	301	
demonstrated	no	significant	difference	in	the	overall	microbiome	composition	of	stool(30).	302	
So,	in	contrast	with	in	vitro	studies,	which	demonstrate	activity	against	a	broad-spectrum	of	303	
bacteria(34),	the	effects	of	Rifaximin	in	vivo	may	be	on	bacterial	function	and	virulence,	304	
rather	than	simply	a	reduction	in	numbers(35,	36).	The	observation	in	the	present	study	that	305	
urinary	hippurate	levels	decreased	with	Rifaximin	therapy	is	relevant	as	urinary	hippurate	is	306	
influenced	by	the	intestinal	microbiota	(as	well	as	age,	sex	and	dietary	intake,	which	were	307	
controlled	for	in	the	present	study)(37).	Hippurate	is	a	glycine	conjugate	of	benzoic	acid	and	308	
a	normal	constituent	of	the	human	urinary	metabolite	profile.	Germ-free	mice	have	309	
significantly	lower	levels	of	urinary	hippurate	than	conventially	raised	mice(38)	and	310	
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administration	of	vancomycin	to	mice	leads	to	changes	in	the	faecal	microbiome	and	311	
associated	suppression	of	urinary	hippurate	levels(39).	Metabolism	of	high-molecular	312	
weight	polyphenolic	compounds	by	colonic	microbiota	leads	to	production	of	benzoic	acid	313	
which	may	be	excreted	as	hippurate(37).	Differential	capacities	of	microbiota	species	to	314	
metabolise	polyphenolic	compounds(40)	means	that	antibiotic-mediated	changes	in	315	
bacterial	numbers	or	population	composition	may	alter	the	bioavailability	of	upstream	316	
metabolites	of	benozoic	acid	and	this	lead	to	changes	in	urinary	hippurate	levels.	Benzoic	317	
acid	is	converted	to	hippurate	predominantly	in	hepatic	mitochondria	and	impaired	hepatic	318	
function	is	associated	with	a	decreased	capacity	to	produce	hippurate	from	orally	or	319	
intravenously	administered	precursors(41,	42).	Thus	there	is	some	evidence	that	the	320	
transient	depression	in	urinary	hippurate	levels	with	Rifaximin	in	this	study	is	mediated	by	321	
suppression	of	such	activity	by	colonic	microbiota.	322	
This	work	indicates	that	the	use	of	a	minimally-absorbed,	broad	spectrum	antibiotic	is	not	323	
associated	with	consistent	changes	in	the	stool	microbiota	at	the	phylum	or	genus	level,	but	324	
suggests	a	metabolic	effect,	illustrated	by	the	urinary	hippurate	levels.	Nevertheless,	such	325	
an	intervention	has	not	led	to	detectable	changes	in	ALT,	insulin	sensitivity	and	hepatic	326	
steatosis,	nor	is	it	associated	with	a	robust	pattern	of	inflammatory	cytokines.	This	study	327	
does	not	support	the	use	of	antibiotics	as	a	therapeutic	intervention	in	NASH,	but	suggests	a	328	
possible	adverse	metabolic	effect	which	needs	further	evaluation.	The	variable	effect	of	this	329	
intervention	at	a	genus	level	between	patients	indicates	that	future	studies	should	focus	on	330	
functional	niches	rather	than	the	abundance	of	the	microbiota	to	direct	therapy.	Future	331	
therapies	targeting	the	gut	microbiota	will	need	to	be	more	nuanced	to	result	in	beneficial	332	
metabolic	and	inflammatory	modulation.	333	
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Administration	of	Rifaximin	for	6	weeks	to	subjects	with	non-alcoholic	steatohepatitis	was	334	
not	associated	with	changes	in	markers	of	hepatocellular	damage,	hepatic	triglyceride	335	
content,	insulin	sensitivity	or	systemic	inflammation	at	6	weeks,	although	an	increase	in	336	
serum	ALT	levels	was	noted	at	12	weeks,	associated	with	increased	HOMA-IR	and	HDL.	On	337	
the	basis	of	the	evidence	presented	in	this	study,	Rifaximin	cannot	be	recommended	as	a	338	
potential	therapy	in	NAFLD/NASH,	but	further	studies	are	warranted	to	investigate	the	339	
hepatic	and	metabolic	consequences	of	enteric	antibiotic	therapies.		340	
	341	
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Table	1.	Baseline	Characteristics.		471	
Characteristic	 Total	cohort	
Number	 15	
Gender,	M/F	 13/2	
Age,	yrs	 46	(32-63)	
Weight,	kg	 83.8	(66.3-116.0)	
BMI,	kg/m2	 27.2	(22.9-35.3)	
Waist,	cm	 101.9	(86.9-127.3)	
Diabetes,	Y/N	 7/8	
Abdominal	Obesity†,	Y/N	 14/1	
Dyslipidaemia†	,	Y/N	 11/4	
Hypertension†,	Y/N	 9/6	
Metabolic	syndrome†,	Y/N	 9/6	
ALT,	IU/L	 55	(33-191)	
AST,	IU/L	 35	(20-100)	
Triglyceride,	mmol/L	 1.69	(0.94-2.94)	
HDL,	mmol/L	 1.07	(0.73-1.45)	
HOMA	-IR	 3.65	(1.52-	8.18)	
Histology‡	 	
Steatosis,	0/1/2/3	 0/4/8/3	
Ballooning,	0/1/2/3	 0/12/3/0	
Lobular	inflammation,	0/1/2	 0/12/3	
Fibrosis,	0/1/2/3/4	 1/6/4/4/0	
Data	expressed	as	numbers	or	median	(range)	as	appropriate.	†IDF	criteria	2005.	‡	Kleiner	472	
et	al.	2005	473	
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	474	
Table	2.	Anthropometrics	and	metabolic	clinical	chemistry	475	
	 Pre-Rifaximin	(0	
weeks)	
Post-Rifaximin	(6	
weeks)	
†P=	 Post-Rifaximin	(12	
weeks)	
†P=	
BMI,	kg/m2	 27.15	(22.86-35.27)	 27.84	(22.92-35.59)	 0.14	 28.08	(22.73-35.59)	 0.47	
Waist,	cm	 101.9	(86.9-	127.3)	 100.6	(87.7-125.5)	 0.58	 101.5	(87.0-126.0)	 0.27	
HOMA-IR	 3.65	(1.52-8.18)	 4.31	(1.25-8.54)	 0.08	 4.29	(2.04-15.71)	 0.05	
Total	
Cholesterol,	
mmol/L	
4.68	(2.52-5.98)	 4.65	(2.58-7.37)	 0.14	 4.44	(2.75-7.10)	 0.33	
HDL,	mmol/L	 1.07	(0.73-1.45)	 1.11	(0.80-1.45)	 0.18	 1.19	(0.77-1.62)	 0.004	
Triglycerides,	
mmol/L	
1.69	(0.94-2.94)	 1.47	(0.81-3.17)	 0.73	 1.47	(0.76-5.23)	 0.89	
†compared	to	baseline	476	
	 	477	
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FIGURE	LEGENDS	478	
Fig.	1.	Primary	and	secondary	study	endpoints	before	and	after	Rifaximin	therapy.	(A)	479	
Serum	ALT	values	at	baseline,	6	weeks	(end	of	treatment)	and	12	weeks	(6	weeks	after	end	480	
of	treatment).	Individual	patient	data	(n=15).	*	P=0.41	vs	baseline,	#	P=0.02	vs	baseline,	481	
P=0.04	vs	6	wks.	(B)	Intrahepatocellular	lipid	content	(IHCL),	expressed	as	a	percentage,	482	
before	and	after	Rifaximin	therapy.	Individual	patient	data	(N=14).	(C)	Hepatic	insulin	483	
sensitivity	(%	suppression	of	endogenous	glucose	production,	SEGP)	before	and	after	484	
Rifaximin	therapy.	Individual	patient	data,	(N=14).	(D)	Peripheral	insulin	sensitivity	(Rd)	485	
before	and	after	Rifaximin	therapy.	Individual	patient	data	(N=14).	486	
	487	
Fig.	2.	Urinary	metabonomic	analysis.	(A)	Typical	1D-NOSEY	NMR	spectrum	of	urine.	(B)	488	
Scores	plot	from	unsupervised	principal	components	analysis,	coloured	by	timepoint	and	489	
labelled	by	patient	identification	number.	(C)	S-line	loadings	plot	from	OPLS-DA	for	pre-	and	490	
post-	treatment	timepoints.	(D)	Boxplots	of	quantified	metabolites	of	interest	at	each	study	491	
timepoint.	492	
	493	
Fig.	3.	Effect	of	Rifaximin	on	the	phylum	level	composition	of	faeces.	The	heatmap	shows	494	
the	abundance	of	the	phylum-level	16S	rRNA	gene	sequences	for	each	patient	pre	and	post	495	
Rifaximin.	Relative	abundances	of	the	sequence	reads	plotted	are	colour	coded	from	less	496	
(blue)	to	more	abundant	(red).	The	colour	value	shows	log10	fold	changes.	497	
	498	
499	
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